Literature DB >> 22321341

Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.

Polat Turker1, Peter J Bostrom, Marcelo L Wroclawski, Bas van Rhijn, Hannes Kortekangas, Cynthia Kuk, Tuomas Mirtti, Neil E Fleshner, Michael A Jewett, Antonio Finelli, Theo Vander Kwast, Andy Evans, Joan Sweet, Matti Laato, Alexandre R Zlotta.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? The reported discordance between staging on transurethral bladder resection and on radical cystectomy pathology in the literature ranges from 20 to 80%.Correct staging in bladder cancer has direct implications for its management. The upstaging from organ-confined (OC) to non-organ-confined (nOC) disease has been reported in 40% of cases. Lymphovascular invasion (LVI) is a factor known to be associated with poor clinical outcome. Pathological upstaging was observed in our cohort in 40% of cases and most cases (80%) were upstaged from OC to nOC disease. During the study period the frequency of upstaging observed increased. We found LVI (hazard ratio [HR]= 5.07, 95% CI = 3.0-8.3, P < 0.001) and any histological variant variant (HR = 2.77, 95% CI = 1.6-4.8, P < 0.001) to be strong independent predictors of upstaging. Patients with clinical T2 bladder cancer found with upstaging at the time of radical cystectomy had a poorer outcome than patients with no upstaging. Identification of patients at high risk of upstaging at radical cystectomy is key to improving their management and outcome.
OBJECTIVES: To analyse the details of bladder cancer (BC) staging in a large combined radical cystectomy (RC) database from two academic centres. To study rate and time trends, as well as risk factors for upstaging, especially clinical factors associated with staging errors after RC. PATIENTS AND METHODS: Characteristics of patients undergoing RC at University Health Network, Toronto, Canada (1992-2010) and University of Turku, Turku, Finland (1986-2005) were analysed.
RESULTS: Among 602 patients undergoing RC, 306 (51%) had a discordance in clinical and pathological stages. Upstaging occurred in 240 (40%) patients and 192 (32%) patients were upstaged from organ-confined (OC) to non-organ-confined (nOC) disease. During the study period, upstaging became more common in both centres. In multivariate analyses, T2 disease at initial presentation (P= 0.001, odds ratio [OR]= 2.62, 95% confidence interval [CI]: 1.44-4.77), high grade disease (P= 0.01, OR = 2.85, 95% CI: 1.21-6.7), lymphovascular invasion (LVI) (P < 0.001, OR = 5.17, 95% CI: 3.48-7.68), female gender (P= 0.038, OR = 0.6, 95% CI: 0.38-0.97, and histological variants (P < 0.001, OR = 2.77, 95% CI: 1.6-4.8) were associated with a risk of upstaging from OC to nOC disease. Upstaged patients had worse survival rates than patients with correct staging. This was especially significant among patients with carcinoma invading bladder muscle before undergoing RC (16% vs 46% 10-year disease-specific mortality, P < 0.001).
CONCLUSIONS: Upstaging is a common problem and unfortunately no improvements have been observed during the last two decades. LVI and the presence of histological variants are strong predictors of upstaging at the time of RC. Pathologists should be encouraged to report LVI and any histological variant at the time of TURBT.
© 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2012        PMID: 22321341     DOI: 10.1111/j.1464-410X.2012.10939.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  26 in total

1.  The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer.

Authors:  Amir Sherif
Journal:  Transl Androl Urol       Date:  2019-07

2.  Should every patient with muscle-invasive bladder cancer receive neoadjuvant chemotherapy?

Authors:  Moritz Maas; Arnulf Stenzl
Journal:  Transl Androl Urol       Date:  2019-07

3.  Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists.

Authors:  Tina Hsu; Peter C Black; Kim N Chi; Christina M Canil; Bernhard J Eigl; Girish Kulkarni; Scott North; Lori Wood; Alexandre R Zlotta; Anthea Lau; Tony Panzarella; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

4.  Urinary bladder cancer staging in CT urography using machine learning.

Authors:  Sankeerth S Garapati; Lubomir Hadjiiski; Kenny H Cha; Heang-Ping Chan; Elaine M Caoili; Richard H Cohan; Alon Weizer; Ajjai Alva; Chintana Paramagul; Jun Wei; Chuan Zhou
Journal:  Med Phys       Date:  2017-09-05       Impact factor: 4.071

5.  Bladder cancer under staging: still unavoidable?

Authors:  Angelo Naselli; Andrea Guarneri
Journal:  Transl Androl Urol       Date:  2019-12

6.  New developments in the management of nonmuscle invasive bladder cancer.

Authors:  Mark D Tyson; Daniel Lee; Peter Clark
Journal:  Curr Opin Oncol       Date:  2017-05       Impact factor: 3.645

7.  Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer.

Authors:  Meera R Chappidi; Max Kates; Aaron Brant; Alexander S Baras; George J Netto; Phillip M Pierorazio; Noah M Hahn; Trinity J Bivalacqua
Journal:  Urology       Date:  2017-01-16       Impact factor: 2.649

8.  Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

Authors:  Jo-An Seah; Normand Blais; Scott North; Yasmin Rahim; Dean Ruether; Peter C Black; Alexandre R Zlotta; Lori Wood; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

9.  External validation of existing nomograms predicting lymph node metastases in cystectomized patients.

Authors:  Miroslav M Stojadinovic; Rade I Prelevic
Journal:  Int J Clin Oncol       Date:  2014-04-11       Impact factor: 3.402

10.  Scoring system for prediction of lymph node metastasis in radical cystectomy cohort.

Authors:  Miroslav M Stojadinović; Rade Prelević; Arso Vukićević
Journal:  Int Urol Nephrol       Date:  2014-01-29       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.